Loading...
  • genes
  • The mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor (CDKI) genes, the p21 , p27 , and p57 genes, in gastric cancer cells was tested by treating the cells with either the DNA demethylation agent, 5-aza-2′-deoxycytidine or the histone deacetylase inhibitor, n -butyric acid or trichostatin A. RNA expression of the gene was determined by reverse transcription PCR. (aacrjournals.org)
  • melanoma
  • In contrast to BRAF V600E or NRAS G12D-expressing melanocytes, melanoma cells have an inherent resistance to suppression of AP-1 activity by BRAFV600E- or MEK-inhibitors. (harvard.edu)
  • tumor
  • Favorable results with palbociclib and its recent U.S. Food and Drug Administration approval demonstrate that CDK inhibitors with narrow selectivity profiles can have clinical utility for therapy based on individual tumor genetics. (aspetjournals.org)
  • dinaciclib
  • A brief overview of results obtained with ATP-competitive inhibitors such as palbociclib and dinaciclib is presented, followed by a compilation of new avenues that have been pursued toward the development of novel, non-ATP-competitive CDK inhibitors. (aspetjournals.org)
  • These findings support combining dinaciclib with PARP inhibitors for MM therapy. (aacrjournals.org)
  • known
  • This highly effective, functional approach allowed for rapid benchmarking against known CDK inhibitors with undesirable side effects, such as flavopiridol ( Fig. 1B ), and showed SCH 727965 to be a compound with a significantly superior therapeutic profile. (aacrjournals.org)